Phesgo 60 mg

PHESGO 60 MG is a subcutaneous solution containing trastuzumab, used for targeted therapy in certain cancer treatments. This medication is designed for subcutaneous administration and is manufactured by Hoffmann-La Roche Limited in Canada.

PHESGO 60 MG is primarily used in the treatment of specific types of cancer, particularly those that involve the HER2 protein. It is often prescribed as part of a targeted therapy regimen to help manage and treat certain cancers. The medication works by targeting and blocking the action of the HER2 protein, which can be overproduced in some cancer cells, leading to their growth and division.

Common effects of PHESGO 60 MG may include reactions at the injection site, such as redness, swelling, or pain. Some individuals may also experience fatigue, nausea, or fever. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

PHESGO 60 MG should be handled with care and administered as directed by a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions you have before starting this medication. Store the solution at the recommended temperature and keep it out of reach of children.

PHESGO 60 MG may interact with other medications, including those that affect the immune system or other cancer treatments. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and certain foods may also affect how this medication works, so it is best to follow your healthcare provider's advice regarding diet and lifestyle.